24 / 61
Notes:
Volume10, Issue 12 (Suppl)
J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 80
conferenceseries
.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20
th
International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9
th
WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
RhoGDI3 and the novel role in carcinogenesis: Pancreatic Ductal Adenocarcinoma (PDAC)
Rocío Thompson Bonilla
1
, Mercedes Piedad de León-Bautista
1,2,3
, Daniel Marrero
3,4
, Mauricio Salcedo
4
, Lorena Gorgonio-Eusebio
3
, Emma Vélez-Uriza
3
and
Miguel Vargas
3
1
ISSSTE, Mexico
2
ACentral AND, Mexico
3
CINVESTAV-IPN, Mexico
4
XXI Century National Medical Center, Mexico
R
hoGDI proteins have been described as small GTPases negative regulators, sequestering GTPases in cytosol avoiding their
activation; nevertheless, there is evidence about their implication in cancer, particularly RhoGDI1 and RhoGDI2 but not
in RhoGDI3. In our group, we have reported an imbalance among the RhoGDI3 protein and three different staging cells, from
non-cancerous to highly aggressive cancerous pancreatic cells; normal and low expression levels respectively. To elucidate the
possible functions of RhoGDI3 in this pathology process, we performed reconstitution assays in the cancerous pancreatic cell
line (PANC-1), which let us know that, normal levels of RhoGDI3 protein produces a smaller tumor compared with the cells
not reconstituted and that the different levels of RhoGDI3 regulated gene expression, such as TRIO, EPHA2, RHEB, KLF10,
EGFR, all of them implicated in cancerous process and tumor maintenance. There are very few proofs about the RhoGDI3 and
the correlation with cancer, specifically PDAC, and our findings open up a gap to expand knowledge, from the RhoGDI3 as a
negative regulator, the classical function, to a RhoGDI3 protein with novel role, decreasing the malignant behavior in PDAC.
Biography
Rocío Thompson Bonilla has completed her Bachelor’s Degree at UNAM and her MSc and PhD from ENCB-IPN in the Dept. of Immunology and PhD in Rutgers
University in 2010. She served as Director of Research in ISSSTE, the second public health institution in Mexico. She won the national price of Biomedicine in 2015
and has been working with infection diseases and with developing molecular platforms to find new markers in cancer and hereditary diseases.
rociothompson@yahoo.com.mxRocío Thompson Bonilla et al., J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110